Showing results (191-200 of 223) with videos related to

Sort By:
Pageof 23
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2009
Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone, and dutasteride in asymptomatic castration-resistant prostate cancerMary-Ellen Taplin, Meredith M Regan, Yoo-Joung Ko, et al.
Biorxiv : the Preprint Server for Biology|March 3, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 7, 2009
Knockin of mutant PIK3CA activates multiple oncogenic pathwaysJohn P Gustin, Bedri Karakas, Michele B Weiss, et al.
JCI Insight|November 16, 2023
MYC-driven increases in mitochondrial DNA copy number occur early and persist throughout prostatic cancer progressionJiayu Chen, Qizhi Zheng, Jessica L Hicks, et al.
European Urology Oncology|June 16, 2020
Metastasis-directed Therapy Prolongs Efficacy of Systemic Therapy and Improves Clinical Outcomes in Oligoprogressive Castration-resistant Prostate CancerMatthew P Deek, Kekoa Taparra, Ryan Phillips, et al.
JAMA Oncology|August 22, 2024
Olaparib Without Androgen Deprivation for High-Risk Biochemically Recurrent Prostate Cancer Following Prostatectomy: A Nonrandomized Controlled TrialCatherine H Marshall, Benjamin A Teply, Jiayun Lu, et al.
BMC Cancer|July 1, 2017
A phase II randomized trial of Observation versus stereotactic ablative RadiatIon for OLigometastatic prostate CancEr (ORIOLE)Noura Radwan, Ryan Phillips, Ashley Ross, et al.
The Lancet. Oncology|December 18, 2017
Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort studyBenjamin A Teply, Hao Wang, Brandon Luber, et al.
Nature Communications|January 3, 2024
Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trialMark C Markowski, Mary-Ellen Taplin, Rahul Aggarwal, et al.
International Journal of Radiation Oncology, Biology, Physics|August 18, 2020
Patterns of Recurrence and Modes of Progression After Metastasis-Directed Therapy in Oligometastatic Castration-Sensitive Prostate CancerMatthew P Deek, Kekoa Taparra, Dyda Dao, et al.
Pageof 23